logo
Plus   Neg
Share
Email

Boston Scientific Backs FY19 Outlook - Quick Facts

While reporting financial results for the second quarter, Boston Scientific Corp. (BSX) on Wednesday maintained its adjusted earnings and revenue growth guidance for the full-year 2019 and also provided outlook for the third quarter.

For fiscal 2019, the company continues to project adjusted earnings in a range of $1.54 to $1.58 per share on revenue growth in a range of about 7 to 8 percent and organic revenue growth in a range of about 7 to 8 percent.

On average, analysts polled by Thomson Reuters expect earnings of $1.56 per share on revenue growth of 8.4 percent to $10.65 billion for the year. Analysts' estimates typically exclude special items.

For the third quarter, the company estimates earnings in a range of $0.23 to $0.25 per share and adjusted earnings, excluding certain charges (credits), in a range of $0.37 to $0.39 per share. It anticipates revenue growth of about 8 to 10 percent and organic revenue growth of about 7.5 to 9 percent.

Analysts expect earnings of $0.39 per share on revenue growth of 10.6 percent to $2.65 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
Follow RTT